Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis

180Citations
Citations of this article
127Readers
Mendeley users who have this article in their library.

Abstract

The expression of selected microRNAs (miRNAs) known to be involved in the regulation of immune responses was analyzed in 74 patients with relapsing remitting multiple sclerosis (RRMS) and 32 healthy controls. Four miRNAs (miR-326, miR-155, miR-146a, miR-142-3p) were aberrantly expressed in peripheral blood mononuclear cells from RRMS patients compared to controls. Although expression of these selected miRNAs did not differ between treatment-naïve (n = 36) and interferon-beta treated RRMS patients (n = 18), expression of miR-146a and miR-142-3p was significantly lower in glatiramer acetate (GA) treated RRMS patients (n = 20) suggesting that GA, at least in part, restores the expression of deregulated miRNAs in MS. © 2011 Waschbisch et al.

Cite

CITATION STYLE

APA

Waschbisch, A., Atiya, M., Linker, R. A., Potapov, S., Schwab, S., & Derfuss, T. (2011). Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS ONE, 6(9). https://doi.org/10.1371/journal.pone.0024604

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free